(BOSTON, MA) – CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens. This is ContraFect’s second antibacterial project to earn CARB-X funding.

 

Credit: CDC

Read more…

The post CARB-X FUNDS CONTRAFECT TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT SERIOUS INFECTIONS CAUSED BY GRAM-NEGATIVE ESKAPE SUPERBUGS appeared first on Healthier Environment Living Program.